Intravenous / Subcutaneous Immunoglobulin from Grifols.
Gamunex-C is a versatile immunoglobulin product from Grifols, approved for both intravenous and subcutaneous administration. This dual approval makes it useful for patients who may transition between infusion routes over time.
Gamunex-C is FDA-approved for the following indications:
When used as IVIG, Gamunex-C is administered every three to four weeks. When used as SCIG, it is administered weekly via self-infusion.
The manufacturer offers a patient support program — Grifols Patient Assistance Program — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.grifolspatientassistanceprogram.com.
Treatment with Gamunex-C is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. This is a subcutaneous self-administered medication. After prior authorization, the prescription is sent to a specialty pharmacy that ships the medication directly to the patient. A manufacturer-sponsored nurse or office-based training visit is typically arranged for the first dose so patients are confident with self-administration before continuing at home.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.gamunex-c.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Gamunex-C is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.